

## [Desmopressin](#)

Essential medicine status

Section:

[10. Medicines affecting the blood](#) [10.2. Medicines affecting coagulation](#)

ATC codes: [H01BA02](#)

EMLc

Indication

Haemophilia A ICD11 code: [3B10.0](#)

INN

Desmopressin

Medicine type

Chemical agent

List type

Core

Formulations

**Parenteral > General injections > IV:** 4 µg per mL in 1 mL ampoule (acetate)

**Local > Nasal > Spray:** 150 µg per actuation (acetate)

EML status history

First added in 1991 ([TRS 825](#))

Changed in 1993 ([TRS 850](#))

Removed in 2003 ([TRS 920](#))

Added in 2015 ([TRS 994](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Desmopressin](#)

DrugBank

[Desmopressin](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes for the listing of desmopressin: - removal of desmopressin nasal spray 10 micrograms per dose - addition of desmopressin nasal spray 150 micrograms per actuation - changes to the description of the listing to correctly describe the strength of the formulations in micrograms of desmopressin acetate, and to reflect the delivered amount of nasal spray per actuation, rather than per dose (since a dose may comprise more than one actuation (spray)). Following consideration of the submission from the World Federation of Hemophilia which included a request to transfer the current listings of plasma-derived coagulation factors from the complementary to the core list, the Expert Committee recommended that the listing for desmopressin also be transferred from the complementary to the core list.